DBV Technologies (NASDAQ:DBVT) Issues Earnings Results

DBV Technologies (NASDAQ:DBVT) announced its earnings results on Thursday. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.48), FiscalAI reports. The business had revenue of $0.70 million for the quarter, compared to analyst estimates of $0.78 million. DBV Technologies had a negative return on equity of 129.88% and a negative net margin of 2,895.37%.

DBV Technologies Price Performance

Shares of DBVT stock traded down $0.85 during trading on Thursday, hitting $14.86. 378,468 shares of the stock traded hands, compared to its average volume of 292,122. DBV Technologies has a 52-week low of $8.51 and a 52-week high of $26.18. The firm has a market capitalization of $879.86 million, a P/E ratio of -3.33 and a beta of -0.95. The firm’s fifty day moving average price is $17.34 and its 200-day moving average price is $19.54.

Analyst Ratings Changes

A number of analysts have commented on DBVT shares. Wall Street Zen downgraded shares of DBV Technologies from a “hold” rating to a “sell” rating in a report on Saturday, July 4th. Guggenheim restated a “buy” rating and set a $51.00 target price on shares of DBV Technologies in a report on Monday, May 4th. HC Wainwright restated a “buy” rating on shares of DBV Technologies in a research report on Tuesday, June 30th. Citizens Jmp increased their price target on DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a report on Tuesday, June 30th. Finally, Citigroup reiterated an “outperform” rating on shares of DBV Technologies in a research report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $48.50.

Institutional Investors Weigh In On DBV Technologies

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DBVT. Truvestments Capital LLC grew its holdings in shares of DBV Technologies by 71.3% during the 4th quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock worth $75,000 after purchasing an additional 1,620 shares during the period. Royal Bank of Canada purchased a new position in DBV Technologies during the fourth quarter worth about $34,000. Persistent Asset Partners Ltd acquired a new stake in shares of DBV Technologies during the fourth quarter valued at about $115,000. Cetera Investment Advisers purchased a new stake in shares of DBV Technologies in the 4th quarter valued at approximately $251,000. Finally, Two Sigma Investments LP acquired a new position in DBV Technologies during the third quarter worth $167,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.